SuperworthFibroBiologics EPS FBLG
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$5.59
- Latest quarter, Q2 FY26
- −$0.66
- Fiscal year 2025
- −$8.72
FibroBiologics' earnings per share was −$5.59 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.66.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$8.72 | n/a |
| FY2024 | −$6.80 | n/a |
| FY2023 | −$13.60 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.66 | n/a | −$5.59 | |
| Q1 FY26 | −$1.33 | n/a | −$7.34 | |
| Q4 FY25 | −$1.00 | n/a | −$8.72 | |
| Q3 FY25 | −$2.60 | n/a | −$9.52 | |
| Q2 FY25 | −$2.41 | −502% | −$7.12 | |
| Q1 FY25 | −$2.71 | n/a | −$4.11 | |
| Q4 FY24 | −$1.80 | n/a | −$6.80 | |
| Q3 FY24 | −$0.20 | n/a | −$11.80 | |
| Q2 FY24 | $0.60 | n/a | −$13.20 | |
| Q1 FY24 | −$5.40 | n/a | −$15.40 | |
| Q4 FY23 | −$6.80 | n/a | −$13.60 | |
| Q3 FY23 | −$1.60 | n/a | n/a |
Against its peers
Companies in Healthcare nearest FibroBiologics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| FBLGFibroBiologics | −$5.59 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on FibroBiologics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.